Efficacy of Elbasvir/Grazoprevir in Early Chronic G1/G4 Hepatitis C infection in HIV/HCV co-infected patients with mild fibrosis

Josep Mallolas(Hospital Clínic de Barcelona), Ana Gonzalez‐Cordón, Alfonso Cabello(Hospital Universitario Fundación Jiménez Díaz), Maria Martínez‐Rebollar(Hospital Clínic de Barcelona), Berta Torres, Elisa de Lazzari(Hospital Clínic de Barcelona), Beatriz Álvarez(Hospital Universitario Fundación Jiménez Díaz), Miguel Górgolas(Hospital Universitario Fundación Jiménez Díaz), Lorena de la Mora(Hospital Clínic de Barcelona), Laura Lorente Prieto(Hospital Universitario Fundación Jiménez Díaz)
Gastroenterología y Hepatología
October 9, 2020
10.1016/j.gastrohep.2020.06.019
Cited by 2

Related Papers

Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain
|PLoS ONE|2018|179
Severe Dengue Virus Infection in Travelers: Risk Factors and Laboratory Indicators
|The Journal of Infectious Diseases|2007|173
Hospital-Acquired Infectious Endocarditis Not Associated with Cardiac Surgery: An Emerging Problem
|Clinical Infectious Diseases|1995|170
The Spectrum of Cardiovascular Infections due to Salmonella enterica
|Medicine|2004|155
Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial
|The Lancet Infectious Diseases|2015|143